Effects of oleoyl-estrone with dexfenfluramine, sibutramine or phentermine on overweight rats.
We studied the combination of oleoyl-estrone with either dexfenfluramine, sibutramine or phentermine in overweight male rats treated for 10 days in order to determine whether they shared a mechanism of action. Oleoyl-estrone, dexfenfluramine and sibutramine decreased body weight and energy (essentially lipids); losses were higher when combined with oleoyl-estrone. Glycemia was maintained except under phentermine; oleoyl-estrone induced decreases in triacylglycerols, cholesterol, insulin and HOMA (homeostasis model assessment). Combination of oleoyl-estrone and sibutramine resulted in the loss of up to 29% body energy in 10 days. Energy expenditure was maintained. The effects of oleoyl-estrone and dexfenfluramine or sibutramine on appetite were substantially additive. All oleoyl-estrone-treated rats showed increased insulin sensitivity. In conclusion, combined treatment of overweight rats with oleoyl-estrone and sibutramine or dexfenfluramine results in a dramatic loss of weight and fat, whilst maintaining circulating energy homoeostasis.
Ferrer-Lorente
Raquel
R
Department of Nutrition and Food Science, Faculty of Biology, University of Barcelona, Av. Diagonal, 645, 08028 Barcelona, Spain.
Cabot
Cristina
C
Fernández-López
José-Antonio
JA
Remesar
Xavier
X
Alemany
Marià
M
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D003503:Cyclobutanes / Q000494:pharmacology* / Q000627:therapeutic use; D020372:Dexfenfluramine / Q000494:pharmacology* / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004734:Energy Metabolism; D004970:Estrone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D009829:Oleic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D010645:Phentermine / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar
D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D007328:Insulin; D008055:Lipids; D009829:Oleic Acids; D004970:Estrone; C108709:oleoyl-estrone; D010645:Phentermine; D020372:Dexfenfluramine; C058254:sibutramine